Brief: Shanghai Henlius Biotech Updates On NDA For New Indication Of Hansizhuang
04/12/2024 12:24
Dec 4 (Reuters) - Shanghai Henlius Biotech Inc
2696.HK :
* NDA FOR NEW INDICATION OF HANSIZHUANG (SERPLULIMAB
INJECTION) IN
COMBINATION WITH CHEMOTHERAPY APPROVED BY NMPA
Further company coverage: 2696.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shanghai Henlius Biotech
See all newsBrief: Shanghai Henlius Biotech Says Wenjie Zhang Resigns As Chairman
Brief: Shanghai Henlius Biotech Enters Collaboration And License Agreement With Amberstone Biosciences
Brief: Shanghai Henlius Biotech Says NDA For 120 Mg Biosimilar Denosumab HLX14 Accepted By NMPA
China's Henlius H1 revenue jumps on drug sales, license income
Brief: Shanghai Henlius Biotech Logs HY Profit RMB 430.4 Mln